Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.

BACKGROUND:Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV). METHODS:The study was conducted in 75 patient...

Full description

Bibliographic Details
Main Authors: Nobuyuki Matsumoto, Hiroki Ikeda, Ryuta Shigefuku, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Tetsuya Hiraishi, Tomohiro Tamura, Yohei Noguchi, Yasunobu Fukuda, Toshiya Ishii, Chiaki Okuse, Akira Sato, Michihiro Suzuki, Fumio Itoh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4798293?pdf=render

Internet

http://europepmc.org/articles/PMC4798293?pdf=render

Similar Items